+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tissue Regenix Ltd - Product Pipeline Analysis, 2021 Update

  • PDF Icon

    Company Profile

  • 55 Pages
  • December 2021
  • GlobalData
  • ID: 5519751
Tissue Regenix Ltd (Tissue Regenix), a subsidiary of Tissue Regenix Group PLC, is a medical technology company that offers replacement body parts from biological materials by using the dCELL technology platform. The company’s proprietary dCELL technology process is applied in markets such as vascular, biosurgery, cardiac and orthopaedics. Its products include human heart valve, tissue matrix, decellurised human dermis product, porcine meniscus, porcine tendon, donated human meniscus and donated human tendon. The company collaborates with universities and other institutions for its research activities. Tissue Regenix is headquartered in Leeds, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Tissue Regenix Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:


  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Tissue Regenix Ltd Company Overview
  • Tissue Regenix Ltd Company Snapshot
  • Tissue Regenix Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Tissue Regenix Ltd - Pipeline Analysis Overview
  • Tissue Regenix Ltd - Key Facts
  • Tissue Regenix Ltd - Major Products and Services
  • Tissue Regenix Ltd Pipeline Products by Development Stage
  • Tissue Regenix Ltd Ongoing Clinical Trials by Trial Status
  • Tissue Regenix Ltd Pipeline Products Overview
  • Cardiopure - Aortic Heart Valve
  • Cardiopure - Aortic Heart Valve Product Overview
  • Cardiopure - Pulmonary Heart Valve
  • Cardiopure - Pulmonary Heart Valve Product Overview
  • dCELL - Small Diameter Graft
  • dCELL - Small Diameter Graft Product Overview
  • dCELL Human Dermis - Plastic Surgery
  • dCELL Human Dermis - Plastic Surgery Product Overview
  • DermaPure - ACL Repair
  • DermaPure - ACL Repair Product Overview
  • Dermapure - Acute Wounds
  • Dermapure - Acute Wounds Product Overview
  • OrthoPure HM
  • OrthoPure HM Product Overview
  • Orthopure HT
  • Orthopure HT Product Overview
  • OrthoPure XM
  • OrthoPure XM Product Overview
  • OrthoPure XM Clinical Trial
  • Orthopure XT
  • Orthopure XT Product Overview
  • Orthopure XT Clinical Trial
  • Orthopure XT - LCL
  • Orthopure XT - LCL Product Overview
  • Orthopure XT - MCL
  • Orthopure XT - MCL Product Overview
  • Orthopure XT - MPFL
  • Orthopure XT - MPFL Product Overview
  • Orthopure XT - PCL
  • Orthopure XT - PCL Product Overview
  • Orthopure XT - PLC
  • Orthopure XT - PLC Product Overview
  • Tissue Regenix Ltd - Key Competitors
  • Tissue Regenix Ltd - Key Employees
  • Tissue Regenix Ltd - Locations And Subsidiaries
  • Head Office
Recent Developments
  • Tissue Regenix Ltd, Recent Developments
Apr 28, 2021: Tissue Regenix Group Announces final results for the year ended 31 December 2020
Feb 26, 2021: Tissue Regenix Announces Directorate Change
Oct 03, 2019: Tissue Regenix launches DermaPure product line extension specifically for surgical and trauma markets
Jun 04, 2019: Tissue Regenix Group: Annual results for the year ended 31 December 2018
Apr 04, 2019: Tissue Regenix Group: Expands US GPO coverage for DermaPure into 1,500 additional hospitals
Dec 17, 2018: Tissue Regenix’s decellularized human dermis product, DermaPure, demonstrated substantial clinical and cost benefits in case series presented at Cleveland Clinic accredited VEITH Symposium
Dec 05, 2018: Tissue Regenix Group: Interim management change
Nov 13, 2018: Tissue Regenix Group: Pan European distribution agreement with Arthrex
Sep 05, 2018: Tissue Regenix Group: Unaudited Interim Results for the six months ended 30 June 2018
Jul 04, 2018: Tissue Regenix Appoints Gareth Hywel Jones As Chief Financial Officer
Appendix
  • Methodology
  • About The Publisher
  • Contact The Publisher
  • Disclaimer

List of Tables
  • Tissue Regenix Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Tissue Regenix Ltd Pipeline Products by Equipment Type
  • Tissue Regenix Ltd Pipeline Products by Indication
  • Tissue Regenix Ltd Ongoing Clinical Trials by Trial Status
  • Tissue Regenix Ltd, Key Facts
  • Tissue Regenix Ltd, Major Products and Services
  • Tissue Regenix Ltd Number of Pipeline Products by Development Stage
  • Tissue Regenix Ltd Pipeline Products Summary by Development Stage
  • Tissue Regenix Ltd Ongoing Clinical Trials by Trial Status
  • Tissue Regenix Ltd Ongoing Clinical Trials Summary
  • Cardiopure - Aortic Heart Valve - Product Status
  • Cardiopure - Aortic Heart Valve - Product Description
  • Cardiopure - Pulmonary Heart Valve - Product Status
  • Cardiopure - Pulmonary Heart Valve - Product Description
  • dCELL - Small Diameter Graft - Product Status
  • dCELL - Small Diameter Graft - Product Description
  • dCELL Human Dermis - Plastic Surgery - Product Status
  • dCELL Human Dermis - Plastic Surgery - Product Description
  • DermaPure - ACL Repair - Product Status
  • DermaPure - ACL Repair - Product Description
  • Dermapure - Acute Wounds - Product Status
  • Dermapure - Acute Wounds - Product Description
  • OrthoPure HM - Product Status
  • OrthoPure HM - Product Description
  • Orthopure HT - Product Status
  • Orthopure HT - Product Description
  • OrthoPure XM - Product Status
  • OrthoPure XM - Product Description
  • OrthoPure XM - dCell Vascular Patch in Biological Repair for Damaged Menisci for CE Mark Submission
  • Orthopure XT - Product Status
  • Orthopure XT - Product Description
  • Orthopure XT - A Prospective, Non-comparative Clinical Investigation of a Novel Decellularised Porcine Xenograft (dCELL ACL Scaffold) for Reconstruction of the Anterior Cruciate Ligament
  • Orthopure XT - LCL - Product Status
  • Orthopure XT - LCL - Product Description
  • Orthopure XT - MCL - Product Status
  • Orthopure XT - MCL - Product Description
  • Orthopure XT - MPFL - Product Status
  • Orthopure XT - MPFL - Product Description
  • Orthopure XT - PCL - Product Status
  • Orthopure XT - PCL - Product Description
  • Orthopure XT - PLC - Product Status
  • Orthopure XT - PLC - Product Description
  • Tissue Regenix Ltd, Key Employees
  • Glossary

List of Figures
  • Tissue Regenix Ltd Pipeline Products by Equipment Type
  • Tissue Regenix Ltd Pipeline Products by Development Stage
  • Tissue Regenix Ltd Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Napp Pharmaceuticals Ltd
  • SB Drug Discovery Ltd
  • Arecor Therapeutics Plc